Definition

A preparation of autologous T lymphocytes that has been genetically engineered to express a switchable, alpha-peptide neo-epitope (PNE) chimeric antigen receptor (CAR) with a binding domain that can recognize a 14 aa peptide epitope, or PNE, of an antigen-specific adapter molecule, with potential immunomodulating and antineoplastic activities. Upon administration, autologous alpha-PNE switchable CAR T (sCART) cells CLBR001 remain inactivated. Upon administration of an antigen-specific adapter molecule, the binding domain of CLBR001 binds to the PNE of the adapter molecule, and CLBR001 is activated. This induces selective toxicity in and causes lysis of tumor cells expressing the specific antigen.